New pharmacological agents such as SGLT2 inhibitors or GLP-1 receptor agonists, used in the treatment of T2DM, have a beneficial effect on carbohydrate metabolism, implicitly modulating the functional status of patients included in cardiovascular recovery programs (class I, level A recommendation according to the ESC guidelines [5]). Here, SLC5A2 is linked to type 2 diabetes mellitus.